Venture Capital

As AI costs soar and security risks mount, a new open-source microhypervisor aims to rebuild trust from the silicon up. Is this the architectural shift we need?

A tectonic shift is underway in how we get paid. Driven by AI and new laws, compensation is moving from a back-office task to a strategic business driver.

A new partnership brings advanced embryo screening to the Pacific, promising healthier babies while igniting a global race and fierce ethical debates.

With the hire of Dr. David Feygin, Outcome Capital signals a major bet on AI-driven advisory, reflecting a broader arms race in healthcare finance.

Nixxy Inc.'s radical pivot to a 1GW energy-first AI platform with Tachyon9 highlights a new industry truth: the AI race is now a power race.

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

New research reveals Indigenous-led projects are not just a social good, but a critical economic engine for Canada's energy transition and resource economy.

Alumni Ventures, a top US firm, launches a London office and a new Global Alumni Syndicate, aiming to reshape VC access for international investors.

As Vivos Therapeutics pitches its revolutionary sleep apnea solution to investors, it's not just selling a device; it's fighting for its financial life.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

As FACE Coalition’s Melamoon tour lands in Halifax, it's clear this is more than a pitch contest. It’s a strategic move to dismantle systemic barriers.

Horizon Growth's new CEO isn't just a management change; it's the final piece in a year-long transformation from a niche carbon firm to a diversified investor.

A Toronto meeting signals a new era for Canada-Grenada ties. It's a calculated move into geothermal energy, regional security, and high-value trade.

Allen Control Systems' massive funding for its autonomous Bullfrog weapon reveals a new reality: venture capital is now funding the future of warfare.

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

A new breed of fund offers Main Street a taste of Silicon Valley's private unicorns. But as Powerlaw Corp. opens the door, are investors ready for the risks?

A $90M investment in a homeless shelter is more than charity; it's a blueprint. Sun Life's model signals a shift from philanthropy to strategic impact investing.

As America rebuilds its industrial base, one firm is tearing down silos, offering a single-source solution of capital and real estate to power the economy.

With corporate boards under intense scrutiny, Quinlan Partners' strategic hires of Lisa Silverman and Mark Skertic signal a new era of proactive defense.

A new diagnostic tool, Delve Detect, is using metagenomic sequencing to unmask elusive pathogens in the brain, offering hope where conventional tests fail.